NCT03011580View on ClinicalTrials.gov

Vitamin D to Resolve Inflammation After Tuberculosis (ResolveD-TB)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

August 1, 2019

Conditions
Recurrent Tuberculosis
Interventions
DIETARY_SUPPLEMENT

Fultium-D3

Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.

DIETARY_SUPPLEMENT

Placebo

3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.

Trial Locations (1)

E1 1BB

Barts Health NHS Trust, London

All Listed Sponsors
lead

Queen Mary University of London

OTHER

NCT03011580 - Vitamin D to Resolve Inflammation After Tuberculosis (ResolveD-TB) | Biotech Hunter | Biotech Hunter